<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616470</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1271-301</org_study_id>
    <nct_id>NCT03616470</nct_id>
  </id_info>
  <brief_title>Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin
      antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to
      chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be
      investigated in patients with relapsed/refractory AML
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from the date of randomization into the study to the date of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of severe oral mucositis</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Incidence of severe oral mucositis experienced in patients after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Proportion of subjects who achieve a complete remission [CR] or CR with partial recovery [CRh] of blood counts</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of remission</measure>
    <time_frame>2 years</time_frame>
    <description>Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Frequency, severity, and relatedness of adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic exposure (amount of uproleselan in the blood)</measure>
    <time_frame>up to 6 days</time_frame>
    <description>The amount of uproleselan in the blood over time.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Uproleselan (GMI-1271)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Saline, 0.9% Sodium Chloride)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uproleselan</intervention_name>
    <description>A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin</description>
    <arm_group_label>Uproleselan (GMI-1271)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline, 0.9% Sodium Chloride</description>
    <arm_group_label>Placebo (Saline, 0.9% Sodium Chloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years and ≤75 years in age

          -  Patients with relapsed or refractory AML

          -  No more than one prior stem cell transplant

          -  Has not received the chemotherapy regimen to be used for induction on this trial

          -  Is considered medically eligible to receive the chemotherapy regimen to be used for
             induction on this trial

        Exclusion Criteria:

          -  Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage
             (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or
             secondary refractory AML.

          -  Active signs or symptoms of CNS involvement by malignancy.

          -  Stem cell transplantation ≤4 months prior to dosing.

          -  Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other
             experimental therapy or chemotherapy within 14 days of dosing.

          -  Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.

          -  Inadequate organ function.

          -  Abnormal liver function.

          -  Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.

          -  Moderate kidney dysfunction (glomerular filtration rate &lt;45 mL/min).

          -  Uncontrolled acute life-threatening bacterial, viral, or fungal infection.

          -  Clinically significant cardiovascular disease.

          -  Major surgery within 4 weeks of dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J DeAngelo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GlycoMimetics, Inc.</last_name>
    <phone>240-243-1201</phone>
    <email>clinicaltrials@glycomimetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moore Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesika Reiner, MPH</last_name>
      <phone>858-822-5364</phone>
      <email>Jreiner@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Wieduwilt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cali Mori</last_name>
      <phone>650-498-8903</phone>
      <email>cmori16@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tu Vy Nguyen</last_name>
      <email>tuvy@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gabriel Mannis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffany Lim</last_name>
      <phone>916-734-0561</phone>
      <email>sllim@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Jonas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason, MLS, CCRC</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Blum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital - Medical Tower</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Brown</last_name>
      <phone>404-780-7965</phone>
      <email>Stacey.brown@northside.com</email>
    </contact>
    <investigator>
      <last_name>Melhelm Solh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Morrison</last_name>
      <phone>913-588-7585</phone>
      <email>mmorrison3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Anurag K Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel J DeAngelo, MD, PhD</last_name>
      <phone>617-632-2645</phone>
      <email>Daniel_Deangelo@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel DeAngelo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Tolksdorf, BS, CCRP</last_name>
      <phone>313-576-9814</phone>
      <email>tolksdoe@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Jay Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayan Gasanli</last_name>
      <phone>314-747-2449</phone>
      <email>agasanli@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Haney</last_name>
      <phone>314-454-8708</phone>
      <email>haneym@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Geoffrey Uy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Przespolewski, DO</last_name>
      <phone>716-845-7110</phone>
      <email>Amanda.Przespolewski@RoswellPark.org</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Walinski</last_name>
      <email>Wendy.Walinski@RoswellPark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Przespolewski, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Tallman, MD</last_name>
      <phone>646-608-2122</phone>
      <email>TallmanM@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Martin Tallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Roboz, MD</last_name>
      <phone>646-962-2700</phone>
      <email>gar2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Gail Roboz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon DeLorme</last_name>
      <phone>585-275-5295</phone>
      <email>Brandon_Delorme@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jane Liesveld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System (DUHS)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Cooper, MD</last_name>
      <phone>216-884-3951</phone>
      <email>brenda.cooper@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Advani, MD</last_name>
      <phone>216-445-9354</phone>
      <email>ADVANIA@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Anjali Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center and James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dienno</last_name>
      <phone>614-293-0752</phone>
      <email>Jennifer.Dienno@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bhavana Bhatnagar, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Jones</last_name>
      <phone>214-820-1970</phone>
      <email>lisa.jones2@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Micah Burch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naval Daver, MD</last_name>
      <phone>713-794-4392</phone>
      <email>NDaver@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval Daver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pena</last_name>
      <phone>801-213-4233</phone>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Tibor Kovacsovics, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niall Curley</last_name>
      <phone>206-606-1231</phone>
      <email>Ncurley8@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Pamela Becker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Gambrill</last_name>
      <phone>+61 2 40144891</phone>
      <email>Michele.Gambrill@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Anoop Enjeti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Perth</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Hay</last_name>
      <phone>+61 (0)8 6383 3207</phone>
      <email>louise.hay@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Aparna Chauhan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gavin Cull, MBBS, FRACP, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelvin Robertson</last_name>
      <phone>07 4433 1628</phone>
      <email>KELVIN.ROBERTSON@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Hock-Choong Lai, MBBS, FRACP, FRCPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Kelly</last_name>
      <email>jason.kelly2@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Paula Marlton, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bakhtiyor Khalikulov</last_name>
      <phone>+61 (8) 8204 5453</phone>
      <email>bakhtiyor.khalikulov@sa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Ali Morshed</last_name>
      <email>aliazammohammad.morshed@sa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Ashanka Beligaswatte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Clinical Trials Centre (CCTC)</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Hawking</last_name>
      <phone>+61 3 9496 9720</phone>
      <email>Joanne.HAWKING@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Chun Y Fong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>THE LEUKEMIA/BMT PROGRAM OF BC Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasim Lowlaavar</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>22967</phone_ext>
      <email>Nasim.lowlaavar1@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sakshi Rana</last_name>
      <email>Sakshi.rana@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Florian Kuchenbauer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network (UHN) - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2MG</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Schuh, MD</last_name>
      <phone>416-581-7893</phone>
      <email>Andre.Schuh@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Schuh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Princess Margaret Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovais Shaikh</last_name>
      <phone>780-407-3365</phone>
      <email>Ovais.Shaikh@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Joseph Brandwein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <zip>H91 TK33</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Walsh</last_name>
      <phone>091893314</phone>
      <email>Jessica.Walsh@nuigalway.ie</email>
    </contact>
    <investigator>
      <last_name>Janusz Krawczyk, MSc, MRCP (I), FRCPath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza Hospital</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, MD</last_name>
      <phone>+39 0882 410566</phone>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Valente</last_name>
      <email>d.valente761@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Cascavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Cerchione, MD, PhD</last_name>
      <phone>+39 0543 739292</phone>
      <email>claudio.cerchione@irst.emr.it</email>
    </contact>
    <contact_backup>
      <last_name>Federica Frabetti</last_name>
      <email>federica.frabetti@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Cerchione, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Lanza, MD, PhD</last_name>
      <phone>+39 0544 285103</phone>
      <email>francesco.lanza@auslromagna.it</email>
    </contact>
    <contact_backup>
      <last_name>Costa Alessandra</last_name>
      <email>alessandra.costa@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Francesco Lanza, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ca' Foncello Hospital</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Gottardi, MD, PhD</last_name>
      <phone>+390422322477</phone>
      <email>michele.gottardi@aulss2.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Chiara Zaina</last_name>
      <email>chiara.zaina@aulss2.veneto.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Gottardi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC (former VUMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian van der Laan</last_name>
      <phone>+31204443534</phone>
      <email>l.laan@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <email>onderzoeksmedicatie@amsterdamumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jeroen J.W.M. Janssen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrikus Boersma</last_name>
      <phone>+31503614331</phone>
      <email>h.h.boersma@umcg.nl</email>
    </contact>
    <contact_backup>
      <email>trials@apoth.umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Emanuele Ammatuna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna van Rhenen, MD, PhD</last_name>
      <phone>+31 88 75 558 78</phone>
      <email>A.vanRhenen@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Klaartje Nijssen</last_name>
      <email>C.A.Nijssen@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Anna van Rhenen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro De Alcantra</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M Bergua Burgues, MD, PhD</last_name>
      <phone>(+34)927621546</phone>
      <email>jmberguaburg@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carmen A Gracia</last_name>
      <email>mamenalca@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Juan M Bergua Burgues, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M A Dominguez, MD</last_name>
      <phone>+34 915504800</phone>
      <phone_ext>3673</phone_ext>
      <email>juan.adominguez@fjd.es</email>
    </contact>
    <contact_backup>
      <last_name>Arantxa G Raso</last_name>
      <email>ArGarciaR@quironsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan M A Dominguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria, Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Pascual</last_name>
      <phone>(+34)951032556</phone>
      <email>carol-imabitiema@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aurora Hernández Sierra</last_name>
      <email>eecchematohuvv@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Fortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana A Pierola, MD, PhD</last_name>
      <phone>(+34) 948 255400</phone>
      <email>aalfonso@unav.es</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Vera</last_name>
      <email>bvera@unav.es</email>
    </contact_backup>
    <investigator>
      <last_name>Ana A Pierola, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria B Vidriales Vicente, MD</last_name>
      <phone>616708202</phone>
      <email>mbvidriales@saludcastillayleon.es</email>
    </contact>
    <contact_backup>
      <last_name>Magdalena Garcia</last_name>
      <phone>616884422</phone>
      <email>mgarcia.ibsal@saludcastillayleon.es</email>
    </contact_backup>
    <investigator>
      <last_name>Maria B Vidriales Vicente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Gonzalez Echezarreta</last_name>
      <phone>(+34) 942 31 53 21</phone>
      <email>pigonec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mercedes Colorado, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montesinos, MD, PhD</last_name>
      <phone>+34961244925</phone>
      <email>montesinos_pau@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>David Pellicer</last_name>
      <email>pellicer_dav@gva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Pau Montesinos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Relapsed AML</keyword>
  <keyword>Refractory AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

